MARLBOROUGH, Mass – Sunovion Pharmaceuticals will conduct a Phase 4 clinical study of the seizure-reducing drug Aptiom using the Embrace watch by Empatica. “We believe that incorporating digital health technologies into traditional treatment paradigms has the potential to inform and enhance best practices and further empower people living with serious medical conditions and their families,” said Dr. Antony Loebel, Sunovion’s executive vice president and chief medical officer, in a statement. The watch will be used to detect and record partial-onset seizures subjectively identified by patients or caregivers—the first time that a wearable seizure detection device has been incorporated into the trial design of an anti-epileptic drug for partial-onset seizures such as Aptiom. The study will enroll approximately 190 adults with partial-onset seizures, and will evaluate the impact on seizure frequency, safety, mood and quality of life measures.
You are here: / / Sunovion incorporates digital health technologies